Metraipolis › archive › dc_0701c7acccb4
Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of… — Europe PMC PMID:41127391
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41127391
- DOI
- 10.3389/fmed.2025.1641245
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T13:08:53.328Z
- SHA-256 of the archived text
dcc25107dcbf82b72621e0bf49be226ee2292fa9651846646ebee045e40ae311- Stable URL of this page
https://metraipolis.com/documento/dc_0701c7acccb4
How to cite
Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of… — Europe PMC PMID:41127391 — Europe PMC (en), https://europepmc.org/article/MED/41127391 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0701c7acccb4 (Metraipolis archive dc_0701c7acccb4, sha256 dcc25107dcbf82b72621e0bf49be226ee2292fa9651846646ebee045e40ae311)
BibTeX
@misc{dc0701c7acccb4,
title = {Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of… — Europe PMC PMID:41127391},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41127391},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0701c7acccb4; sha256 dcc25107dcbf82b72621e0bf49be226ee2292fa9651846646ebee045e40ae311},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41127391. Agents can read the archived copy with the MCP tool read_document.